טוען...
Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication
Oncolytic herpes simplex virus (HSV) is currently in phase III clinical trials for development as a novel therapeutic agent against a broad range of human tumors. Although results have been promising, clinical outcome is likely to be compromised by intrinsic and acquired resistance to HSV replicatio...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3133790/ https://ncbi.nlm.nih.gov/pubmed/21128236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.25808 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|